These technologies allow precise identification of immune cell subsets (e.g., distinct Treg or TAM populations), spatial mapping of cytokine/chemokine gradients, and localization of pathway activations (e.g., VEGF, HIF-1α) within tumor niches. The gene discussed is VEGFA; the disease is neoplasm.